Securisyn Medical

Securisyn Medical is a pre-revenue, late-stage development company preparing for the U.S. commercial launch of its flagship product, the SolidAIRity® Flex for adults, in late 2024, with a pediatric version expected in 2026. The company targets a critical and costly complication in intensive care—unplanned extubation—with a differentiated securement technology. Led by a seasoned team with clinical, operational, and commercial expertise, Securisyn is positioned to address a significant unmet need in hospital airway safety, though its success hinges on successful market entry and adoption against established competitors.

The SolidAIRity® Airway Stabilization System, a novel endotracheal tube securement device platform designed to prevent unplanned extubation in mechanically ventilated patients.

Securisyn competes in the ETT securement market against simple adhesive tapes (the dominant, low-cost method) and several commercial tube-holder devices from companies like Dale Medical, Medline, and Cardinal Health. Its differentiation strategy is based on superior security and safety outcomes, positioning it as a premium, value-added solution rather than a commodity.